title: Association between hepatitis C virus infection and development of posttransplantation diabetes mellitus in renal transplant recipients.
abstract: BACKGROUND
  Posttransplantation diabetes mellitus (PTDM) is a metabolic complication of renal transplantation. A high prevalence of DM has been recently reported in patients with chronic hepatitis C virus (HCV) infection in the nontransplant population. The aim of this study was to investigate possible factors that may have a role in the development of DM, including HCV infection in renal transplant recipients.
  
  
  METHODS
  This case-control study included 43 patients with PTDM (36 men, 7 women; mean age, 44+/-10 years) and 43 consecutive transplant patients who did not develop PTDM (30 men, 13 women; mean age, 37+/-11 years). Age, body mass index, high-dose steroid use, family history for DM and HCV, and presence of HLA-DR2, -DR3, and -DR4 were considered as possible factors for predicting PTDM.
  
  
  RESULTS
  Patients with PTDM were older (P=0.002) and had a higher prevalence of family history of DM (61% vs. 9%, P<0.001) and a higher rate of HCV seropositivity (72% vs. 37%, P=0.002; odds ratio = 1.94; 95% confidence interval = 1.26-2.98). The prevalence of pancreatic autoantibodies (anti-glutamic acid decarboxylase, islet cell antibody) was similar between patients with and without PTDM. In logistic regression analysis (r = 0.61, P<0.001), age, family history, and HCV infection were independent variables for predicting development of PTDM.
  
  
  CONCLUSIONS
  HCV infection was associated with the development of PTDM, in addition to family history and increased age. The rate of autoantibodies against pancreatic cells was not increased in patients with HCV, which suggested that nonimmunologic mechanisms were likely to have a role in the pathogenesis of PTDM.
authors.affiliation: Department of Internal Medicine, Division of Nephrology, Istanbul School of Medicine, 34390 Topkapi, Istanbul, Turkey. alaattiny@hotmail.com
authors.forename: Alaattin
authors.initials: A
authors.lastname: Yildiz
authors.forename: Yildiz
authors.initials: Y
authors.lastname: Tütüncü
authors.forename: Halil
authors.initials: H
authors.lastname: Yazici
authors.forename: Vakur
authors.initials: V
authors.lastname: Akkaya
authors.forename: S Mehmet
authors.initials: SM
authors.lastname: Kayacan
authors.forename: Mehmet Sükrü
authors.initials: MS
authors.lastname: Sever
authors.forename: Mahmut
authors.initials: M
authors.lastname: Carin
authors.forename: Kubilay
authors.initials: K
authors.lastname: Karşidağ
mesh_terms: D000328:Adult; D017677:Age Distribution; D016022:Case-Control Studies; D003922:Diabetes Mellitus, Type 1 / Q000453:epidemiology* / Q000821:virology; D005260:Female; D018937:Hepatitis C Antibodies / Q000097:blood; D019698:Hepatitis C, Chronic / Q000453:epidemiology* / Q000276:immunology; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage; D007328:Insulin / Q000008:administration & dosage; D007676:Kidney Failure, Chronic / Q000453:epidemiology / Q000601:surgery / Q000821:virology; D016030:Kidney Transplantation; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000453:epidemiology* / Q000821:virology; D015995:Prevalence
chemical_list: D018937:Hepatitis C Antibodies; D007004:Hypoglycemic Agents; D007328:Insulin